当代多国心力衰竭患者患病率、结局与费用:CaReMe HF研究
患者合并症负担重,心肾疾病事件率和医院费用最高。
要点
- 宽泛定义心衰患病率为2.01%(95%CI 1.65-2.36),严格定义为1.05%(0.85-1.25)。
- 心衰患者中心肾疾病事件率最高(19.3/100患者年),全因死亡率13.1/100患者年。
- 医院费用以心肾疾病最高,主要由心衰或CKD住院驱动。
核心结论
- 当代成年人群约1-2%患有心衰,不良结局和费用风险显著,主要由心衰或CKD住院驱动。
主要发现
- 宽泛定义心衰患病率2.01%(95%CI 1.65-2.36),严格定义1.05%(0.85-1.25)。
- 心衰患者平均年龄75.2岁(95%CI 74.0-76.4),48.8%合并缺血性心脏病,34.5%合并糖尿病。
- 心肾疾病事件率19.3/100患者年(95%CI 11.3-27.1),全因死亡率13.1/100患者年(11.1-15.1)。
关键数值与推荐
- 宽泛定义:任何注册的心衰诊断;严格定义:有心衰住院史。
- 事件率以每100患者年报告,医院费用累计计算至5年。
临床怎么用
- 临床应关注心衰患者心肾共病管理,优化治疗以降低住院和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Digital healthcare systems could provide insights into the global prevalence of heart failure (HF). We designed the CardioRenal and Metabolic disease (CaReMe) HF study to estimate the prevalence, key clinical adverse outcomes and costs of HF across 11 countries. METHODS: Individual level data from a contemporary cohort of 6 29 624 patients with diagnosed HF was obtained from digital healthcare systems in participating countries using a prespecified, common study plan, and summarised using a random effects meta-analysis. A broad definition of HF (any registered HF diagnosis) and a strict definition (history of hospitalisation for HF) were used. Event rates were reported per 100 patient years. Cumulative hospital care costs per patient were calculated for a period of up to 5 years. RESULTS: The prevalence of HF was 2.01% (95% CI 1.65 to 2.36) and 1.05% (0.85 to 1.25) according to the broad and strict definitions, respectively. In patients with HF (broad definition), mean age was 75.2 years (95% CI 74.0 to 76.4), 48.8% (40.9-56.8%) had ischaemic heart disease and 34.5% (29.4-39.6%) had diabetes. In 51 442 patients with a recorded ejection fraction (EF), 39.1% (30.3-47.8%) had a reduced, 18.8% (13.5-24.0%) had a mildly reduced and 42.1% (31.5-52.8%) had a preserved left ventricular EF. In 1 69 518 patients with recorded estimated glomerular filtration rate, 49% had chronic kidney disease (CKD) stages III-V. Event rates were highest for cardiorenal disease (HF or CKD) and all cause mortality (19.3 (95% CI 11.3 to 27.1) and 13.1 (11.1 to 15.1), respectively), and lower for myocardial infarction, stroke and peripheral artery disease. Hospital care costs were highest for cardiorenal diseases. CONCLUSIONS: We estimate that 1-2% of the contemporary adult population has HF. These individuals are at significant risk of adverse outcomes and associated costs, predominantly driven by hospitalisations for HF or CKD. There is considerable public health potential in understanding the contemporary burden of HF and the importance of optimising its management.
引用
- Norhammar, Bodegard, Vanderheyden, et al. Prevalence, outcomes and costs of a contemporary, multinational population with heart failure. Heart. 2023. PMID: 36781285. doi:10.1136/heartjnl-2022-321702
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。